Dr. Kota is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1120 15th St
Augusta, GA 30912Phone+1 706-721-2423Fax+1 706-721-1459
Summary
- Dr. Vamsi Kota is an oncologist in Augusta, GA. He received his medical degree from Armed Forces Medical College Pune and has been in practice 14 years. He is experienced in hematologic oncology, multiple myeloma, and leukemia.
Education & Training
Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2008 - 2011- Medical College of GeorgiaResidency, Internal Medicine, 2004 - 2007
ArMed Forces Medical College PuneClass of 2003
Certifications & Licensure
GA State Medical License 2007 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia Start of enrollment: 2016 Oct 01
- Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia Start of enrollment: 2017 Aug 03
- Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
- Join now to see all
Publications & Presentations
PubMed
- 41 citationsIdentification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.Pankaj Ahluwalia, Ashis K. Mondal, Chance Bloomer, Sadanand Fulzele, Kimya Jones
International Journal of Molecular Sciences. 2019-08-05 - 4 citationsEthno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.Pankaj Ahluwalia, Ashutosh Vashisht, Harmanpreet Singh, Nikhil Shri Sahajpal, Ashis K Mondal
Journal of Medical Virology. 2023-09-01 - 9 citationsCross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.Nidhi Mehra, Armon Varmeziar, Xinyu Chen, Olivia Kronick, Rachel Fisher
Cancers. 2022-09-26
Abstracts/Posters
- Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline UpdatesVamsi Kota, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integr...Vamsi Kota, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Help Desk for Oncologists Treating People with a Rare Leukemia Pays Big DividendsFebruary 2nd, 2023- 'It Was Miraculous:' Cancer Patient First to Get New Immunotherapy at AU Health SystemMay 27th, 2021
Cassie Mitchell: Competing for Team USA in the Paralympic GamesSeptember 7th, 2016- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
